NEOS Investment Management LLC Buys Shares of 22,557 Nurix Therapeutics, Inc. (NASDAQ:NRIX)

NEOS Investment Management LLC purchased a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 22,557 shares of the company's stock, valued at approximately $425,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of NRIX. Vanguard Group Inc. increased its holdings in Nurix Therapeutics by 8.3% during the 4th quarter. Vanguard Group Inc. now owns 4,345,266 shares of the company's stock worth $81,865,000 after purchasing an additional 333,452 shares during the period. Wellington Management Group LLP grew its holdings in Nurix Therapeutics by 8.8% during the 3rd quarter. Wellington Management Group LLP now owns 3,482,105 shares of the company's stock worth $78,243,000 after acquiring an additional 280,240 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Nurix Therapeutics by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,448,040 shares of the company's stock valued at $32,544,000 after purchasing an additional 126,306 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Nurix Therapeutics by 42.7% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company's stock valued at $14,869,000 after purchasing an additional 235,971 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. lifted its position in shares of Nurix Therapeutics by 42.8% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 789,222 shares of the company's stock worth $14,869,000 after purchasing an additional 236,620 shares during the last quarter.

Remove Ads

Analysts Set New Price Targets

A number of analysts have weighed in on the company. BTIG Research began coverage on Nurix Therapeutics in a research note on Tuesday, December 10th. They issued a "buy" rating and a $35.00 price target on the stock. HC Wainwright restated a "buy" rating and set a $36.00 target price on shares of Nurix Therapeutics in a research note on Wednesday. Morgan Stanley raised their price objective on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the stock an "equal weight" rating in a report on Monday, February 3rd. Leerink Partnrs upgraded shares of Nurix Therapeutics to a "hold" rating in a report on Monday, March 17th. Finally, JPMorgan Chase & Co. cut their price target on shares of Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Three investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $30.88.

Nurix Therapeutics Trading Down 7.8 %

Shares of NRIX traded down $0.82 during trading hours on Friday, reaching $9.69. The company had a trading volume of 1,490,801 shares, compared to its average volume of 911,426. The company has a market capitalization of $738.73 million, a price-to-earnings ratio of -3.35 and a beta of 2.23. Nurix Therapeutics, Inc. has a 12-month low of $9.45 and a 12-month high of $29.56. The firm has a 50 day simple moving average of $15.45 and a 200-day simple moving average of $19.89.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. Sell-side analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Insider Buying and Selling at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 5,825 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $14.49, for a total value of $84,404.25. Following the sale, the chief financial officer now directly owns 33,724 shares of the company's stock, valued at approximately $488,660.76. This represents a 14.73 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gwenn Hansen sold 3,690 shares of the firm's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the transaction, the insider now owns 55,937 shares of the company's stock, valued at $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,326 shares of company stock valued at $213,449. Insiders own 7.20% of the company's stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.